ALK and anemia: In terms of safety, as emerged from metanalyses [33], the spectrum of toxicities of ALK-TKIs differed, with anemia and constipation being more frequent with alectinib, whereas changes in lipid levels were the most frequent AEs associated with lorlatinib.